Reviewing RedHill Biopharma Ltd. (RDHL)’s and Pfenex Inc. (NYSEAMERICAN:PFNX)’s results

As Biotechnology companies, RedHill Biopharma Ltd. (NASDAQ:RDHL) and Pfenex Inc. (NYSEAMERICAN:PFNX) are our subject to compare. And more specifically their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RedHill Biopharma Ltd. 9.00M 27.65 41.55M -1.94 0.00
Pfenex Inc. 29.41M 4.13 27.28M -0.99 0.00

Table 1 shows the gross revenue, earnings per share and valuation for RedHill Biopharma Ltd. and Pfenex Inc.


Table 2 represents RedHill Biopharma Ltd. (NASDAQ:RDHL) and Pfenex Inc. (NYSEAMERICAN:PFNX)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
RedHill Biopharma Ltd. -461.67% 0% 0%
Pfenex Inc. -92.76% -43.7% -32.3%

Institutional & Insider Ownership

The shares of both RedHill Biopharma Ltd. and Pfenex Inc. are owned by institutional investors at 26.06% and 84.4% respectively. Insiders owned roughly 5.84% of RedHill Biopharma Ltd.’s shares. On the other hand, insiders owned about 0.1% of Pfenex Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
RedHill Biopharma Ltd. -17% -15.9% -5.55% -3.99% 41.01% 35.8%
Pfenex Inc. -7.49% -15.08% -26.49% -32.81% 70.22% 43.98%

For the past year RedHill Biopharma Ltd. was less bullish than Pfenex Inc.


On 7 of the 10 factors Pfenex Inc. beats RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. Its clinical-stage pipeline includes TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two European Union member states under the European Decentralized Procedure. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.